GEP20063860B - Chemically-modified human growth hormone conjugates - Google Patents

Chemically-modified human growth hormone conjugates

Info

Publication number
GEP20063860B
GEP20063860B GE5599A GEAP2002005599A GEP20063860B GE P20063860 B GEP20063860 B GE P20063860B GE 5599 A GE5599 A GE 5599A GE AP2002005599 A GEAP2002005599 A GE AP2002005599A GE P20063860 B GEP20063860 B GE P20063860B
Authority
GE
Georgia
Prior art keywords
growth hormone
human growth
chemically
modified human
conjugate
Prior art date
Application number
GE5599A
Inventor
Rory F Finn
Wei Lao
Ned R Siegel
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of GEP20063860B publication Critical patent/GEP20063860B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormones [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Abstract

1. Technical Result Increase in efficiency of treatment of the diseases caused by deficiency of human growth hormone. 2. Essence A conjugate, the structural formula of which is provided in the description comprises at least one poly (ethylene glycol) molecule covalently attached to at least one amino acid residue of a biologically active human growth hormone (hGH) polypeptide or agonist variant thereof; said conjugate is chemically modified human Growth Hormone, which is used for treating the diseases caused by deficiency of human growth hormone. 3. Field of Application Medicine.
GE5599A 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates GEP20063860B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33190701P 2001-11-20 2001-11-20

Publications (1)

Publication Number Publication Date
GEP20063860B true GEP20063860B (en) 2006-06-26

Family

ID=23295870

Family Applications (1)

Application Number Title Priority Date Filing Date
GE5599A GEP20063860B (en) 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates

Country Status (25)

Country Link
EP (1) EP1453859A2 (en)
JP (2) JP2005525302A (en)
KR (2) KR20050044858A (en)
CN (1) CN1608079A (en)
AP (1) AP2004003050A0 (en)
AU (1) AU2002356990A1 (en)
BR (1) BR0214451A (en)
CA (1) CA2467731A1 (en)
CO (1) CO5580794A2 (en)
EA (2) EA200700431A1 (en)
EC (1) ECSP045114A (en)
GE (1) GEP20063860B (en)
HR (1) HRP20040448A2 (en)
HU (1) HUP0500997A2 (en)
IL (1) IL162031A0 (en)
IS (1) IS7268A (en)
MA (1) MA27544A1 (en)
MX (1) MXPA04004809A (en)
NO (1) NO20042182L (en)
OA (1) OA13063A (en)
PL (1) PL374354A1 (en)
RS (1) RS53104A (en)
TN (1) TNSN04090A1 (en)
WO (1) WO2003044056A2 (en)
ZA (1) ZA200403907B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6956135B2 (en) 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
AU2002357806A1 (en) * 2001-12-11 2003-06-23 Sun Bio, Inc. Novel monofunctional polyethylene glycol aldehydes
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
RS55578B1 (en) * 2002-01-18 2017-06-30 Biogen Ma Inc Polyalkylene polymer compounds and uses thereof
AP2005003249A0 (en) 2002-09-09 2005-03-31 Nektar Therapeutics Al Corp Water-soluble polymer alkanals.
EP1591467A1 (en) * 2002-09-09 2005-11-02 Nektar Therapeutics Al, Corporation Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US20050281778A1 (en) * 2003-03-28 2005-12-22 Myung-Ok Park Human growth hormone conjugated with biocompatible polymer
CN100580087C (en) * 2003-10-10 2010-01-13 诺和诺德医疗保健公司 Conjugation of peptides
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
ATE550041T1 (en) * 2004-01-21 2012-04-15 Novo Nordisk Healthcare Ag TRANSGLUTAMINASE-MEDIATED CONJUGATION OF PEPTIDES
AU2005319099B2 (en) 2004-02-02 2010-09-16 Ambrx, Inc. Modified human growth hormone
MX2007002441A (en) * 2004-08-31 2007-05-04 Pharmacia & Upjohn Co Llc Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof.
CN103290084A (en) * 2004-12-22 2013-09-11 Ambrx公司 Method for expression and purification of recombinant human growth hormone
EP1828224B1 (en) 2004-12-22 2016-04-06 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
WO2006084888A2 (en) 2005-02-10 2006-08-17 Novo Nordisk A/S C-terminally pegylated growth hormones
KR20080013878A (en) 2005-04-18 2008-02-13 노보 노르디스크 에이/에스 Il-21 variants
WO2007025988A2 (en) 2005-08-30 2007-03-08 Novo Nordisk Health Care Ag Liquid formulations of pegylated growth hormone
RS51998B (en) * 2005-11-08 2012-04-30 Ambrx Inc. Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
SG170116A1 (en) 2005-12-14 2011-04-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
EP2040757A2 (en) * 2006-07-07 2009-04-01 Novo Nordisk Health Care AG New protein conjugates and methods for their preparation
CN101108895B (en) * 2006-07-19 2011-10-26 北京键凯科技有限公司 Polyglycol ethanal derivant and combo of medicament and the same
CA2666426A1 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S Il-21 variants
CL2008002399A1 (en) * 2007-08-16 2009-01-02 Pharmaessentia Corp Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c.
EP2272875B1 (en) * 2008-04-03 2014-01-15 Biosteed Gene Expression Tech. CO., LTD. Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof
KR101104574B1 (en) * 2008-05-14 2012-01-11 성균관대학교산학협력단 Human growth hormone derivative linked with polyethyleneglycol, method for the preparation thereof and pharmaceutical composition comprising the same
UA104146C2 (en) * 2008-07-31 2014-01-10 Фармаиссеншиа Корп. POLYMER CONJUGATES OF AN INTERFERON-β MOIETY, AN ERYTHROPOIETIN MOIETY, OR A GROWTH HORMONE MOIETY
US8865868B2 (en) 2008-08-06 2014-10-21 Novo Nordisk Healthcare Ag Conjugated proteins with prolonged in vivo efficacy
RU2409669C9 (en) * 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Method for immobilising biologically active substance (bas) on carrier (versions) and bas-carrier conjugate produced by such methods
JP5766118B2 (en) * 2008-09-11 2015-08-19 ウェルズ ファーゴ バンク ナショナル アソシエイション Polymeric alpha-hydroxyaldehyde and ketone reagents and conjugation methods
AU2010207725B2 (en) 2009-01-22 2015-06-11 Novo Nordisk Health Care Ag Stable growth hormone compounds
JP6086528B2 (en) 2009-08-06 2017-03-01 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー Growth hormone with long-term in vivo efficacy
BR112012014721B1 (en) 2009-12-15 2022-06-28 Ascendis Pharma Endocrinology Division A/S GROWTH HORMONE COMPOSITIONS, THEIR MANUFACTURING METHODS, CONTAINER AND KIT
MX345736B (en) 2010-01-22 2017-02-14 Novo Nordisk Healthcare Ag Growth hormones with prolonged in-vivo efficacy.
EP2525833A2 (en) 2010-01-22 2012-11-28 Novo Nordisk Health Care AG Stable growth hormone compounds
EP2571896A4 (en) * 2010-05-17 2014-01-08 Cebix Inc Pegylated c-peptide
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
EA019967B1 (en) * 2011-12-21 2014-07-30 Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") Polyethyleneglycol covalent conjugate with human growth hormone
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
EP4282485A3 (en) 2014-11-06 2024-01-17 PharmaEssentia Corporation Dosage regimen for pegylated interferon
CA2978330C (en) * 2015-03-11 2024-01-09 Nektar Therapeutics Conjugates of an il-7 moiety and a polymer
CN108026182B (en) 2015-09-18 2022-04-26 国立大学法人宫崎大学 Long-acting adrenomedullin derivative
CN114539384A (en) * 2020-11-19 2022-05-27 江苏众红生物工程创药研究院有限公司 Pegylated long-acting growth hormone, and preparation method and medical application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
DE69128944T2 (en) * 1990-05-04 1998-06-25 American Cyanamid Co Stabilization of somatotropin through modification of cysteine residues
JPH06506217A (en) * 1991-03-18 1994-07-14 エンゾン，インコーポレーテッド Hydrazine-containing conjugates of polypeptides or glycopolypeptides and polymers
AU2147192A (en) * 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
ES2338431T3 (en) * 1995-09-21 2010-05-07 Genentech, Inc. VARIANTS OF HUMAN GROWTH HORMONE.
IL133974A0 (en) * 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
IL144259A0 (en) * 1999-01-14 2002-05-23 Bolder Biotechnology Inc Methods for making proteins containing free cysteine residues
KR100689212B1 (en) * 1999-01-29 2007-03-09 암겐 인코포레이티드 Gcsf conjugates
AU2001289307A1 (en) * 2000-04-06 2001-10-23 Pharmacia Corporation Chemically-modified myelopoietin conjugates
WO2002055532A2 (en) * 2001-01-11 2002-07-18 Maxygen Aps Variant growth hormone molecules conjugated with macromolecular compounds

Also Published As

Publication number Publication date
CO5580794A2 (en) 2005-11-30
RS53104A (en) 2006-10-27
JP2005525302A (en) 2005-08-25
KR20070072924A (en) 2007-07-06
ZA200403907B (en) 2007-12-27
IS7268A (en) 2004-05-17
BR0214451A (en) 2006-05-30
MA27544A1 (en) 2005-10-03
OA13063A (en) 2006-11-10
EA200400565A1 (en) 2005-06-30
CN1608079A (en) 2005-04-20
JP2006321808A (en) 2006-11-30
HRP20040448A2 (en) 2006-02-28
AU2002356990A1 (en) 2003-06-10
WO2003044056A3 (en) 2003-08-21
HUP0500997A2 (en) 2007-11-28
CA2467731A1 (en) 2003-05-30
IL162031A0 (en) 2005-11-20
MXPA04004809A (en) 2004-08-11
ECSP045114A (en) 2004-07-23
AP2004003050A0 (en) 2004-06-30
KR20050044858A (en) 2005-05-13
PL374354A1 (en) 2005-10-17
NO20042182L (en) 2004-08-11
EA008505B1 (en) 2007-06-29
EA200700431A1 (en) 2008-02-28
WO2003044056A2 (en) 2003-05-30
TNSN04090A1 (en) 2006-06-01
EP1453859A2 (en) 2004-09-08

Similar Documents

Publication Publication Date Title
GEP20063860B (en) Chemically-modified human growth hormone conjugates
CA2078347C (en) Use of copper(ii) containing compounds to accelerate wound healing
JPH02504279A (en) Analog peptides of insulin-like growth factor 1 (IGF-1) or factor 2 (IGF-2)
EA200000601A1 (en) SITE - SPECIFIC RECEPTION OF GRF CONJUGATES WITH POLYETHYLENE GLYCOL
BG100236A (en) Sheared keratiocytic growth factor (kgf) of increased biological activity
MX172600B (en) , "PROCEDURE FOR THE PRODUCTION OF A BIOLOGICALLY ACTIVE PROTEIN
ATE245697T1 (en) CLONING AND EXPRESSION OF A GENE ENCODING BRYODIN 1 FROM BRYONIA DIOICA
UA66857C2 (en) PEG-b-INTERFERON CONJUGATE, METHOD FOR ITS SYNTHESIS, METHOD FOR TREATING INFECTIONS, TUMORS, AUTOIMMUNE AND INFLAMMATORY DISEASES
MXPA02006215A (en) Method for the preparation of 1benzotriazolyl carbonate esters of poly(ethylene glycol).
CY1107051T1 (en) ANTI-ADVENTURES AND ANTI-ANGIROGENIC URKOKINING WASTES AND THEIR USE
AU2005232475A1 (en) Novel g-csf conjugates
KR20070108535A (en) Conjugates of a polypeptide and a pentasaccharide
NZ517012A (en) Peptides that lower blood glucose levels
WO2003061577A3 (en) Polyalkylene glycol with moiety for conjugating biologically active compound
GB2355009A (en) Peptides conjugated to bile acids/salts
EP1763535B1 (en) Polypeptide linked with an organic group
AU5956398A (en) Remedies for lymphocytic tumors
WO2002055532A3 (en) Variant growth hormone molecules conjugated with macromolecular compounds
CA2444266A1 (en) Use of bile acid or bile salt fatty acid conjugates
AR042103A1 (en) CONJUGATES OF HUMAN HUMAN GROWTH PEGILATED N- TERMINALS AND PROCESS FOR PREPARATION
EP1382352A1 (en) Bisacyloxypropylcystein conjugates and the use thereof
YU68702A (en) Novel lhrh-antagonists, production and use thereof as medicament
BR0213821A (en) Polymer / peptide conjugates Thymosin alfa 1
KR890700606A (en) Biologically active molecules
KR960000921A (en) Calcitonin derivatives and uses thereof